Tissue Regenix Group plc
TRX.L
London Stock Exchange7.25
GBp
- -
- -
Tissue Regenix Group plc
TRX.L
(London Stock Exchange)
Recent
price
7.25
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Tissue Regenix Group plc is a pioneering medical technology company specializing in regenerative medicine, focusing on the development and commercialization of regenerative products using two core platform technologies: dCELL, which addresses soft tissue needs, and BioRinse, which provides sterile bone allografts. The company's product portfolio includes soft tissue products such as DermaPure for wound care, OrthoPure XT for orthopedic applications, and AmnioWorks, a birth tissue product used in ophthalmology and wound covering. Its offerings serve diverse surgical applications including biosurgery, orthopedics (sports medicine and spine), dental, general surgery, plastic surgery, urology/gynecology, ophthalmology, and cardiac surgery. Tissue Regenix operates globally with significant presence in the United States, the United Kingdom, and Germany, supported by facilities such as its tissue bank in San Antonio, Texas, and a multi-tissue bank joint venture in Rostock, Germany. The company was founded in 2006 and is headquartered in Leeds, United Kingdom. Recently, Tissue Regenix has strengthened its market position through strategic acquisitions and operational expansions. Notably, the company acquired CellRight Technologies in August 2017, enhancing its regenerative bone scaffold capabilities and expanding its footprint in the U.S. healthcare market. In 2024-2025, Tissue Regenix achieved key regulatory milestones including obtaining MDR certification for its Orthopure XT division and a European patent for its dCELL process, reinforcing its intellectual property position. The company also continued to grow its revenue and product orders, particularly in demineralized bone matrix products and de-cellularized tissue grafts. Additionally, in June 2024, Tissue Regenix acquired property in San Antonio to establish a U.S.-based manufacturing facility, supporting its direct production of patented regenerative products. These developments underline the company's commitment to innovation, expanded global distribution, and increasing its product availability via strategic partnerships and direct sales channels. Tissue Regenix's latest financial and operational updates indicate ongoing investment in research, regulatory compliance, and market expansion to maintain its leadership in regenerative medical technology. Its focus on high-growth product lines in bone grafts, skin (dermis), and birth tissue, combined with a robust patent portfolio and multiple clinical applications, position the company for sustained growth within the advanced medical equipment and biotechnology sectors worldwide. The company currently employs approximately 86 staff, operating from its Leeds headquarters and other international locations to serve healthcare providers across multiple regions. This comprehensive range of advanced regenerative products, backed by strategic acquisitions and regulatory progress, defines Tissue Regenix Group plc as a significant innovator and supplier within the global regenerative medicine industry. It continues to leverage its proprietary technologies and expanding infrastructure to address key clinical needs in soft tissue and bone repair, targeting use across numerous surgical specialties and geographic markets.